Form 4: Director Li Acquires RXRX Stock as Compensation

Recursion Pharmaceuticals Director Dean Y. Li acquired 2,381 shares of Class A Common Stock as part of the company's outside director compensation policy.

Summary

• Dean Y. Li, a Director of Recursion Pharmaceuticals, Inc. (RXRX), acquired 2,381 shares of Class A Common Stock.
• The acquisition occurred on January 2, 2026, at a price of $0 per share.
• These shares were issued under the Issuer's Outside Director Compensation Policy.
• Following this transaction, Dean Y. Li directly owns 1,240,909 shares and indirectly owns 1,979,029 shares through various trusts (Dean Y. Li Revocable Trust: 1,422,048 shares; Dean Y. Li GRAT: 136,981 shares; Dean Y. Li 2021 Family Trust: 421,000 shares).

Sentiment

Score: 6

Explanation: The filing reports a routine stock acquisition by a director as part of their compensation, which is a neutral event but can be seen as slightly positive due to increased insider ownership and alignment of interests.

Positives

• Director Dean Y. Li received 2,381 shares of Class A Common Stock, aligning his interests with shareholders.
• The transaction was made pursuant to a Rule 10b5-1 plan, indicating a pre-arranged, non-discretionary transaction.

Future Outlook

No forward-looking statements or guidance are provided in this insider transaction report.

Industry Context

This is a routine insider transaction, common for public company directors receiving equity as part of their compensation. It does not directly reflect broader industry trends but is a standard practice in corporate governance.

Comparison to Industry Standards

• The issuance of equity as compensation to outside directors is a standard practice across various industries, aligning director incentives with shareholder value.
• The use of a Rule 10b5-1 plan for such transactions is also a common and recommended practice to mitigate concerns about opportunistic insider trading, consistent with best practices in corporate governance.

Corporate Governance

Related Party Transactions

• Acquisition of 2,381 shares of Class A Common Stock by Director Dean Y. Li from Recursion Pharmaceuticals, Inc. as compensation.

Stakeholder Impact

• Shareholders: Increased alignment of the director's financial interests with those of the shareholders through equity compensation.
• Employees: No direct impact on employees is mentioned in this filing.

Key Dates

Recommendation

This Form 4 filing details a routine compensation event where a director received shares as part of their compensation policy. It does not contain information that would significantly alter the investment thesis for Recursion Pharmaceuticals, Inc. While it increases insider ownership, which is generally positive, it's an expected part of director remuneration and not indicative of new strategic developments or financial performance changes. Therefore, a 'hold' recommendation is appropriate based solely on this filing.

Keywords

Recursion Pharmaceuticals, RXRX, Dean Y. Li, Form 4, insider transaction, stock acquisition, director compensation, equity